UK – Ajovy bags NICE approval

The National Institute for Health and Care Excellence (NICE) has recommended Teva’s Ajovy for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.

The decision means that the anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE, offering monthly or quarterly dosing options, with the choice to self-inject once patients are trained.

NICE’s choice to approve the use of Ajovy on the NHS for patients with chronic migraine is “fantastic news,” commented Dr Mark Weatherall, president of the British Association for the Study of Headache. “Anyone who looks after people with chronic migraine understands just how debilitating this neurological disorder can be…